Sarizotan clinical trials
How each study uses sarizotan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2004 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
EMD Serono (3) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Centre for Addiction and Mental Health (1)
Studies
Open first, then newest update. How each study uses sarizotan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated DyskinesiaCompletedPhase 3EMD SeronoNCT00105508Written as Sarizotan
- Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated DyskinesiaCompletedPhase 3EMD SeronoNCT00105521Written as Sarizotan
- Sarizotan in Parkinson Patients With L-dopa-induced DyskinesiaCompletedPhase 2EMD SeronoNCT00314288Written as Sarizotan HCl
- Sarizotan in the Treatment of Neuroleptic-induced Tardive DyskinesiaTerminatedNot applicableCentre for Addiction and Mental HealthNCT00310661Written as Sarizotan
- EMD 128130 for the Treatment of Parkinson's DiseaseCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00009048Written as EMD 128130
Codes
What other systems call sarizotan · ClinicalTrials.gg INT004410
- MeSH (NLM) C443959sarizotanOne source NLM
- UNII (FDA) 467LU0UCUWSARIZOTANConfirmed FDA, NLM, Wikidata
- Wikidata Q7424144sarizotanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77567SarizotanOne source FDA
- DrugBank DB06454One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C443959 | sarizotan | One source NLM |
| UNII (FDA) | 467LU0UCUW | SARIZOTAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7424144 | sarizotan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77567 | Sarizotan | One source FDA |
| DrugBank | DB06454 | — | One source Wikidata |
Also registered as sarizotan hydrochloride (UNII 5P71E6YO9H).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.